Valeant Pharmaceuticals celebrates the manufacturing of four billion bottles of eye care products at Bausch + Lomb's Greenville Solutions Plant
Commemorative bottles specially labelled to denote the batch containing the four billionth bottle were produced for the occasion.
Valeant Pharmaceuticals International has announced that the company celebrated the production of the four billionth bottle of eye care products manufactured at Bausch + Lomb's Greenville Solutions Plant, with Valeant Chairman and CEO J. Michael Pearson joining elected officials, employees, and local business leaders on a tour of the South Carolina facility. Commemorative bottles specially labelled to denote the batch containing the four billionth bottle were produced for the occasion.
The Bausch + Lomb solutions plant has been a staple of the Greater Greenville community for more than 30 years since opening in 1983. The plant employs a workforce of more than 500 employees who help to manufacture more than 30 essential medical products, which are then sent to a nearby shipping facility to be packaged and transported around the world. Among the top global Valeant brands manufactured at the Greenville facility include Biotrue multi-purpose solution, ReNu Solutions, and Boston solutions for gas permeable contact lenses. Many of the Greenville Solutions Plant's employees have worked at the site for more than 10 years.
In addition, Valeant and Bausch + Lomb executives announced a new, state-of-the-art, integrated line investment of approximately $25 million. The expansion, coupled with a previously approved solutions-making investment, will add 40 million units of capacity — an overall increase of more than 20%. More than 30 new jobs will be created from the increase in capacity, with an expected $7 million spent on local construction and engineering firms. Valeant is also committing to new investments of approximately $90 million over the next two years, and approximately $150 million over the next five years, which is expected to result in 150 to 200 new jobs in the next 5 years.
"Reaching this incredible milestone at Bausch + Lomb's Greenville Solutions Plant demonstrates the enormous impact that the facility has had across the globe," said Pearson. "Whether it's one of the hundreds of employees creating our top-of-the-line products, or a consumer who has bought one of our four billion bottles manufactured at this facility for his or her lens care needs, the work that is done here is essential to peoples' lives. We are incredibly proud of the employees in Greenville, who reflect the very best of Valeant Pharmaceuticals."
"Congratulations to the Bausch + Lomb Greenville Solutions Plant on your four billionth bottle, and to 32 years of bringing manufacturing jobs to the Upstate," said Senator Lindsey Graham. "South Carolinians are grateful to have such an essential business in our state, and we look forward to many more years of success and positive community impact."
"Longstanding businesses in our community have provided valuable contributions to our thriving workforce," said Senator Tim Scott. "Being able to celebrate major production milestones underscores the dedication of these businesses in our state, and reinforces South Carolina's role as the center of our nation's manufacturing renaissance."
"Thank you to the Bausch + Lomb Greenville Solutions Plant for the invitation to celebrate the production of its four billionth bottle," said Representative Trey Gowdy. "For over 30 years, the Greenville Bausch + Lomb facility has continued to manufacture and export products worldwide, supporting hundreds of jobs in the Upstate. Congratulations on this achievement."
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance